Background Duloxetine and venlafaxine extended release (venlafaxine XR) are SNRIs
indicated for the treatment of MDD. This study addresses whether duloxetine and …

Purpose/Background This post hoc analysis examined the time point at which clinically
significant improvement in major depressive disorder (MDD) symptoms occurs with …

Major depressive disorder (MDD) is among the most incapacitating conditions in the world.
The emergence of the selective serotonin reuptake inhibitor (SSRI) and serotonin …

Background The aim of this study was to evaluate the impact of desvenlafaxine on a broad
range of major depressive disorder (MDD) symptoms. Methods Data were pooled from 9 …

BACKGROUND: Clinical trials assessing antidepressant therapies typically include separate
assessments of efficacy (benefit) and adverse events (risk). Global benefit–risk (GBR) …

The efficacy, safety, and tolerability of desvenlafaxine (administered as desvenlafaxine
succinate) were evaluated in two similarly designed, phase 3, randomized, double-blind …

This pooled analysis evaluated the efficacy of desvenlafaxine (administered as
desvenlafaxine succinate) for the treatment of major depressive disorder (MDD) in patients …

Objective: To assess short-term efficacy and safety of desvenlafaxine 50 and 100 mg/d
versus placebo for treating major depressive disorder (MDD). Assessment of sexual function …

Desvenlafaxine succinate (DVS) is one of several serotonin-norepinephrine reuptake
inhibitors (SNRIs). Others are venlafaxine hydrochloride, milnacipran, and duloxetine …

The antidepressant efficacy and safety of desvenlafaxine succinate (desvenlafaxine) were
evaluated in a phase III, double-blind, placebo-controlled study. Outpatients with a primary …